Autobahn Therapeutics: Funding, Investors & Team (Sep 2026)
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’s pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego.
Autobahn Therapeutics has raised $109M across 2 funding rounds on record, the most recent an undisclosed round of $32.7M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Autobahn Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Autobahn Therapeutics Funding Rounds
Autobahn Therapeutics raised $76.0M in an undisclosed round announced in Jun 2020.
2.3 years later, an undisclosed round of $32.7M was announced in Sep 2022.
Autobahn Therapeutics Founders and Leadership Team
Contact details for the Autobahn Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Autobahn Therapeutics Funding Compared to Other Biotechnology Startups
Autobahn Therapeutics' latest round of $32.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Autobahn Therapeutics in Biotechnology and San Diego
Companies Similar to Autobahn Therapeutics
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Autobahn Therapeutics Funding FAQs
What does Autobahn Therapeutics do?
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’s pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego.
How much funding has Autobahn Therapeutics raised?
Autobahn Therapeutics has raised $109M across 2 rounds on record. The most recent is an undisclosed round of $32.7M announced in Sep 2022.
When did Autobahn Therapeutics last raise funding?
Autobahn Therapeutics' most recent funding round on record is an undisclosed round of $32.7M, announced in Sep 2022.
Who is the CEO of Autobahn Therapeutics?
Kevin Finney is listed as CEO at Autobahn Therapeutics.
Where is Autobahn Therapeutics headquartered?
Autobahn Therapeutics is based in San Diego, California, United States.
How many employees does Autobahn Therapeutics have?
Autobahn Therapeutics is in the 11-50 employee band.
How does Autobahn Therapeutics' funding compare to other Biotechnology startups?
Autobahn Therapeutics' latest round of $32.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Autobahn Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Autobahn Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.